Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 5/20 | 0.51 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.51 |
| ▸ | KISS1R | Q969F8 | 6/20 | 0.50 |
| ▸ | CTSL | P07711 | 3/20 | 0.50 |
| ▸ | CTSS | P25774 | 3/20 | 0.50 |
| ▸ | CTSK | P43235 | 3/20 | 0.50 |
| ▸ | CTSH | P09668 | 1/20 | 0.50 |
| ▸ | GRPR | P30550 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30294165 | 1.00 | MC4R (0.51) | MC4RC5AR1KISS1RCTSLCTSS | |
| SCHEMBL29717261 | 1.00 | MC4R (0.51) | MC4RC5AR1KISS1RCTSLCTSS | |
| SCHEMBL30294161 | 1.00 | MC4R (0.51) | MC4RC5AR1KISS1RCTSLCTSS | |
| SCHEMBL30294166 | 1.00 | MC4R (0.51) | MC4RC5AR1KISS1RCTSLCTSS | |
| SCHEMBL23968026 | 0.96 | MC4R (0.56) | MC4RKISS1RCTSLCTSSCTSK | |
| SCHEMBL20045522 | 0.96 | MC4R (0.56) | MC4RKISS1RCTSLCTSSCTSK | |
| SCHEMBL20046066 | 0.96 | MC4R (0.56) | MC4RKISS1RCTSLCTSSCTSK | |
| SCHEMBL30294162 | 0.96 | MC4R (0.56) | MC4RKISS1RCTSLCTSSCTSK | |
| SCHEMBL23786601 | 0.91 | MC4R (0.49) | MC4RC5AR1KISS1RCTSLCTSS | |
| SCHEMBL23786544 | 0.91 | MC4R (0.49) | MC4RC5AR1KISS1RCTSLCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11591367-B2 | Melanocortin-1-receptor agonists | DSM IP ASSETS B.V. (NL) | 2023-02-28 | — | — | US | disclosed |
| CN-109803979-B | Melanocortin-1-receptor agonists | 帝斯曼知识产权资产管理有限公司 | 2023-01-31 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11591367-B2 | Melanocortin-1-receptor agonists | MC1R, MC3R, MC5R | MC4R 4/4885C5AR1 72/4885KISS1R 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.